Canadian Society of Vascular Medicine (CSVM)
GLP-1 and Peripheral Artery Disease (PAD)
Learning Objectives:
-
Describe the pathophysiologic rationale for using GLP-1 receptor agonists in patients with or
at risk for Peripheral Artery Disease (PAD) -
Analyze and interpret evidence from major cardiovascular outcome trials regarding GLP-1 receptor agonist therapy in PAD populations
-
Identify appropriate patient populations for GLP-1 receptor agonist therapy beyond glycemic control, considering cardiovascular risk reduction and vascular protection in individuals with or
at risk for PAD -
Integrate GLP-1 receptor agonists into comprehensive PAD management strategies
_edited.jpg)
_edited.jpg)
Joshua A. Beckman, MD MS
Professor, Department of
Internal Medicine
UT Southwestern Medical Center
Dallas, TX
Beth Abramson, MSc MD FRCPC FACC
Associate Professor of Medicine
University of Toronto
Toronto, ON